Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners restated a “buy” rating on shares of Evogene in a research report on Friday, March 7th.

Evogene Price Performance

Evogene stock opened at $1.35 on Wednesday. Evogene has a fifty-two week low of $1.20 and a fifty-two week high of $9.00. The firm’s 50 day simple moving average is $1.49 and its 200-day simple moving average is $1.86. The company has a market cap of $7.24 million, a P/E ratio of -0.30 and a beta of 1.28.

Evogene (NASDAQ:EVGN) last announced its earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.78. The company had revenue of $1.61 million for the quarter, compared to the consensus estimate of $3.63 million. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. During the same period in the previous year, the business earned ($1.30) EPS.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC acquired a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned about 0.30% of Evogene at the end of the most recent quarter. Institutional investors and hedge funds own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.